688399.SH
硕世生物
SSE · Healthcare · Biotechnology · CN
CNY 27.85
−2.76%Year over year
Reported trailing growth
- Revenue
- -6.9%
- EBITDA
- —
- EBIT
- -8.0%
- EPS
- -37.0%
- Free cash flow
- —
- Operating cash flow
- -75.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -60.6%
- EBITDA
- -72.1%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026